How is Rigin related to Palmitoyl Tetrapeptide-7?

Rigin is the base tetrapeptide (Gly-Gln-Pro-Arg). Palmitoyl Tetrapeptide-7 is Rigin conjugated to palmitic acid, which enhances skin penetration and stability for topical use. They share the same active sequence — the palmitoyl version is the cosmeceutical form found in skincare products.

How does Rigin differ from Matrixyl (Palmitoyl Tripeptide-1)?

They have complementary roles. Matrixyl (Pal-GHK) stimulates collagen and ECM production. Rigin (Pal-GQPR) suppresses inflammation that degrades collagen. Together as Matrixyl 3000, they work synergistically — one builds collagen while the other protects it from inflammatory breakdown.

What is Rigin's connection to tuftsin?

Rigin was discovered in 1981 as a structural analog of tuftsin — both are tetrapeptides derived from IgG that stimulate phagocytosis. Rigin comes from the IgG heavy chain (positions 224-227), while tuftsin comes from a different region. They share similar 3D conformations and equivalent immune-stimulating activity.

Rigin

An immunomodulatory tetrapeptide derived from human IgG, used in cosmeceuticals as Palmitoyl Tetrapeptide-7 to suppress skin inflammation (IL-6) and support anti-aging skin repair.

PreliminaryModerate Data Beginner-Friendly

What is Rigin?

Rigin (Gly-Gln-Pro-Arg) is a tetrapeptide originally isolated from the heavy chain of human immunoglobulin G (IgG) in 1981. It was discovered as a structural analog of tuftsin, with equivalent phagocytosis-stimulating activity. In its lipidated form — Palmitoyl Tetrapeptide-7 (formerly Palmitoyl Tetrapeptide-3) — it is widely used in cosmeceutical skincare as an anti-inflammatory peptide. Its primary function in skincare is not collagen stimulation but rather suppression of IL-6, a pro-inflammatory cytokine that accelerates skin aging by driving chronic low-grade inflammation. It is commonly combined with Palmitoyl Tripeptide-1 in the commercial complex Matrixyl 3000 for synergistic anti-aging effects.

Why People Talk About It

Skin anti-inflammation and IL-6 suppression

Preliminary

UV-induced inflammation reduction (topical)

Preliminary

Anti-aging skincare (as Palmitoyl Tetrapeptide-7)

Preliminary

Phagocytosis stimulation and immune modulation

Preliminary

Anti-malarial protection (hydrophobic analogs, preclinical)

Limited

How It Works

Rigin calms skin inflammation. It suppresses IL-6, a key inflammatory molecule that accelerates skin aging when chronically elevated. UV exposure spikes IL-6, which breaks down collagen and weakens skin structure. Rigin dials down this inflammatory signal, protecting the skin's structural proteins from inflammatory damage. Separately, it also stimulates immune cells (phagocytes) to clear debris and pathogens.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Well-tolerated topically in cosmeceutical formulationsNo significant adverse effects reported in skincare use

Cautions

• Not FDA-approved as a drug — marketed as a cosmeceutical ingredient
• Injectable use is not established for humans
• Immune-stimulating properties may be contraindicated in certain autoimmune conditions
• Quality varies across cosmeceutical and research sources

What We Don't Know

Systemic safety of injectable Rigin in humans has not been studied. Long-term topical safety is supported by widespread cosmeceutical use but not by formal clinical trials. The immune-stimulating properties observed in vitro and animal models have not been systematically evaluated in humans.

Published Research

7 studies

The second life of antibodies.

ReviewPMID: 24512657

Determination of an unusual secondary structural element in the immunostimulating tetrapeptide rigin.

PreclinicalPMID: 20629117

Folded conformation of an immunostimulating tetrapeptide rigin: high temperature molecular dynamics simulation study.

PreclinicalPMID: 12413862

Immunomodulatory potential of hydrophobic analogs of Rigin and their role in providing protection against Plasmodium berghei infection.

PreclinicalPMID: 11379040

Characterization of a novel type VII beta-turn conformation for a bio-active tetrapeptide rigin.

PreclinicalPMID: 10691984

Rigin, another phagocytosis-stimulating tetrapeptide isolated from human IgG. Confirmations of a hypothesis.

PreclinicalPMID: 7309346

Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream.

Clinical Trial

Mechanism of Action

Rigin (Gly-Gln-Pro-Arg) is derived from the Fc region of human IgG heavy chain (positions 224-227). It adopts a type VII beta-turn conformation structurally analogous to tuftsin. In its palmitoylated form (Pal-GQPR), it suppresses IL-6 secretion from keratinocytes — in vitro data shows 40-60% IL-6 reduction at 10-100 μM and up to 86% reduction in UV-irradiated cells. IL-6 drives inflammaging in skin by promoting MMP expression, ECM degradation, and impaired collagen synthesis. By reducing IL-6, Rigin indirectly protects ECM integrity. Additionally, it may inhibit MMP activity and stimulate production of laminin IV/V and collagen VII. The unmodified peptide stimulates phagocytosis at levels comparable to tuftsin, activating macrophage-mediated clearance. Hydrophobic analogs (palmitoyl, cholestanyl) showed immunomodulatory protection against Plasmodium berghei in mice, operating through lymphocyte activation rather than macrophage pathways.

Evidence Snapshot

Overall Confidence30%

Human Clinical Evidence

Limited direct clinical data for Rigin alone. A 12-week clinical study of a multi-component eye cream containing Palmitoyl Tetrapeptide-7 showed significant improvements in skin hydration, elasticity, and collagen density, with increased fibroblast proliferation and collagen/elastin synthesis. However, active complexes contained multiple ingredients, making it difficult to attribute effects to Rigin specifically. Widespread cosmeceutical use provides indirect safety evidence.

Animal / Preclinical

Moderate. Hydrophobic Rigin analogs provided significant protection against Plasmodium berghei malaria in mice — prophylactic administration substantially reduced parasitemia and mortality, operating through lymphocyte activation (PMID: 11379040). In vitro data shows dose-dependent IL-6 suppression in keratinocytes and UV-protection effects.

Mechanistic Rationale

Moderate. The IL-6 suppression mechanism is supported by in vitro keratinocyte data from Sederma (the commercial developer). The phagocytosis-stimulating activity is well-established from the original 1981 discovery paper and confirmed by structural studies. The type VII beta-turn conformation has been characterized by NMR and molecular dynamics (PMID: 10691984, 12413862).

Forms & Administration

Rigin is primarily used topically as Palmitoyl Tetrapeptide-7 in cosmeceutical formulations (serums, creams, eye treatments). It is commonly formulated at 50-200 ppm in skincare products, often combined with Palmitoyl Tripeptide-1 as Matrixyl 3000. The unmodified peptide is available as a research compound. Topical cosmeceutical use does not require a prescription.

Use Cases & Evidence Levels

Skin anti-inflammation and IL-6 suppression

Preliminary30%

UV-induced inflammation reduction (topical)

Preliminary30%

Anti-aging skincare (as Palmitoyl Tetrapeptide-7)

Preliminary30%

Phagocytosis stimulation and immune modulation

Preliminary30%

Anti-malarial protection (hydrophobic analogs, preclinical)

Limited15%

Safety Profile

Safety Information

Common Side Effects

Well-tolerated topically in cosmeceutical formulationsNo significant adverse effects reported in skincare use

Cautions

• Not FDA-approved as a drug — marketed as a cosmeceutical ingredient
• Injectable use is not established for humans
• Immune-stimulating properties may be contraindicated in certain autoimmune conditions
• Quality varies across cosmeceutical and research sources

What We Don't Know

Published Research

7 studies

The second life of antibodies.

ReviewPMID: 24512657

Determination of an unusual secondary structural element in the immunostimulating tetrapeptide rigin.

PreclinicalPMID: 20629117

Folded conformation of an immunostimulating tetrapeptide rigin: high temperature molecular dynamics simulation study.

PreclinicalPMID: 12413862

Immunomodulatory potential of hydrophobic analogs of Rigin and their role in providing protection against Plasmodium berghei infection.

PreclinicalPMID: 11379040

Characterization of a novel type VII beta-turn conformation for a bio-active tetrapeptide rigin.

PreclinicalPMID: 10691984

Rigin, another phagocytosis-stimulating tetrapeptide isolated from human IgG. Confirmations of a hypothesis.

PreclinicalPMID: 7309346

Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream.

Clinical Trial

Related Peptides

Palmitoyl Tripeptide-1

ModerateBeginner

A collagen-boosting cosmetic peptide that mimics the body's wound-healing signal to stimulate collagen and elastin production in the skin.

Matrixyl

ModerateBeginner

A collagen-stimulating cosmetic peptide that signals skin to produce more collagen and extracellular matrix proteins.

GHK-Cu

ModerateBeginner

A naturally occurring copper-binding peptide with extensive research on skin remodeling, wound healing, and anti-aging.

Argireline

ModerateBeginner

A cosmetic peptide that reduces wrinkles by inhibiting neurotransmitter release at the neuromuscular junction, often called 'topical Botox.'

SNAP-8

EmergingBeginner

A cosmetic peptide that reduces the appearance of wrinkles by modulating neuromuscular junction signaling.

Quick Facts

Class: Cosmeceutical Peptide
Evidence: Preliminary
Safety: Moderate Data
Updated: Apr 2026
Citations: 7PubMed

Also known as

Palmitoyl Tetrapeptide-7Palmitoyl Tetrapeptide-3Pal-GQPRGly-Gln-Pro-Arg

Evidence Score

Overall Confidence30%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.